MAIA (MAIA Biotechnology) Float Percentage Of Total Shares Outstanding: 91.72% (As of Aug. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MAIA MAIA Biotechnology Inc MAIA
33 GF Score
Price $1.33
! 1 Warning Sign
View Full Analysis

What is MAIA Biotechnology Float Percentage Of Total Shares Outstanding?

MAIA Biotechnology MAIA -3.62% 33 Float Percentage Of Total Shares Outstanding is 91.72% as of Aug. 29, 2026. GuruFocus rates MAIA with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MAIA Biotechnology's float shares is 55.79 Mil. MAIA Biotechnology's total shares outstanding is 60.83 Mil. MAIA Biotechnology's float percentage of total shares outstanding is 91.72%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MAIA Biotechnology's Insider Ownership is 6.35%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MAIA Biotechnology's Institutional Ownership is 21.68%.

MAIA
33GF Score
MAIA Biotechnology Inc MAIA
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MAIA Biotechnology Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

MAIA Biotechnology's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=55.79/60.83
=91.72%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 91.72% mean?
MAIA Biotechnology (MAIA) has a Float Percentage Of Total Shares Outstanding of 91.72% as of Aug. 29, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on MAIA Biotechnology and its competitors.
Is MAIA Biotechnology's Float Percentage Of Total Shares Outstanding too high?
MAIA Biotechnology's current Float Percentage Of Total Shares Outstanding is 91.72%. Overall, MAIA Biotechnology has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does MAIA Biotechnology's Float Percentage Of Total Shares Outstanding compare to GANX and PYPD?
MAIA Biotechnology's Float Percentage Of Total Shares Outstanding of 91.72% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on MAIA Biotechnology and its competitors. MAIA Biotechnology's current Float Percentage Of Total Shares Outstanding is 91.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MAIA Biotechnology stock overvalued right now?
MAIA Biotechnology (MAIA) has a current Float Percentage Of Total Shares Outstanding of 91.72%. The current Float Percentage Of Total Shares Outstanding is 91.72%. MAIA Biotechnology's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For MAIA Biotechnology (MAIA), the current Float Percentage Of Total Shares Outstanding is 91.72% as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MAIA Biotechnology Business Description

Address 444 West Lake Street, Suite 1700, Chicago, IL, USA, 60606
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
33GF Score

Get the complete analysis for MAIA

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price